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Management of advanced 
adult congenital heart disease 
As surgical techniques continue to develop, for example as seen 
with the Norwood procedure for hypoplastic left heart syndrome, 
the number of patients with the most complex forms of CHD will 
continue to increase along with their associated long term com-
plications. Our ability to manage these patients appropriately, 
therefore, must also develop alongside. The purpose of this review 
is to examine the management of these patients once they have 
developed advanced disease, including drug therapy, devices, 
transplant and end of life care. In particular, the unique problems 
posed by patients with a systemic right ventricle (RV) and uni-
ventricular circulations are discussed.
DRUG THERAPY IN HEART FAILURE
In patients with complex congenital heart disease, either palliated 
or unoperated, the development of ventricular dysfunction and 
clinical heart failure are common and as discussed above, is a 
common cause of morbidity and mortality in this population.(7) 
Causes of ventricular dysfunction include longstanding volume or 
pressure overload, cyanosis or surgical insult. It is usually a chronic 
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INTRODUCTION
Due to advances in cardiac surgery and paediatric cardiology, 
increasing numbers of children born with congenital heart disease 
(CHD) are surviving into adulthood.(1-3) As a result there are now 
more adults than children living with CHD.(2,4,5), Furthermore, an 
increasing number of adults are surviving with the more severe 
forms of CHD with Marelli, et al. reporting the prevalence of severe 
CHD in adults increasing by 85% between 1985-2000 compared to 
just 22% in the paediatric population.(4) A recent report by Tutarel, 
et al. from the UK also recently reported an increase of 6-7 fold in 
patients with moderate to severe defects since 2000.(6)
Only the very simple lesions are truly “cured” by surgical or inter-
ventional procedures with the majority of patients remaining at 
long term risk of complications including arrhythmias, ventricular 
failure and premature death.(5) Despite this, mortality has shifted 
away from infancy to adulthood with an increasing age of death 
reported.(7) Whilst the age of death is increasing, this population still 
has an excess mortality compared to their healthy counterparts.(3,8) 
The commonest cause of death in adults with CHD is heart failure, 
accounting for up to 40% of all deaths with sudden cardiac death 
also being a major cause.(3,8-10) Although the majority of deaths are 
cardiac, related to the underlying CHD, non-cardiac mortality was 
also two fold that expected.(3) Furthermore, as this population 
continues to age, they will also be at risk of significant medical co- 
morbidities.(6,11) 
There are increasing numbers of adults with congenital heart 
disease. These patients remain at lifelong risk of complications 
including heart failure, arrhythmias and premature death. 
This review examines the management of those patients with 
advanced disease, with particular reference to patients with 
either a systemic right ventricle or a univentricular circulation.
Drugs used to treat left ventricular dysfunction in acquired 
heart disease have been shown to have little benefi t in this 
setting. There are, however, promising results from small trials 
looking at selective pulmonary vasodilators in patients with a 
previous Fontan operation. Whilst there is evidence of a 
benefi t with implantable cardiac defi brillators and cardiac 
resynchronisation, there remains a lack of clear guidelines as 
to which patients will benefi t from these invasive therapies. 
Cardiac transplantation in these patients is associated with an 
increased early mortality but the long term outcome is 
similar to those with acquired heart failure. Transplantation 
however, is limited by both the patient’s suitability and the 
availability of a matched organ. End of life care should be 
discussed with all patients with advanced disease and ideally 
this should be done early on and in parallel to other therapies. 
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process with the development of clinical features of heart failure 
often occurring after a period of asymptomatic ventricular failure. 
Drug therapy is often first line in the management of these patients, 
with experience gained from acquired heart failure often being 
applied. However, patients with congenital heart disease were 
excluded from all the major chronic heart failure studies and, due 
to their unique anatomical and physiological abnormalities, should 
be considered a very different population. To date, though, most 
trials in this population involve small patient numbers and frequently 
use surrogate end points.(12) Two groups of patients who pose 
specific problems in the management of ventricular failure are those 
with a systemic right ventricle (RV) and a univentricular circulation. 
The RV does not behave like a normal left ventricle (LV) when in 
the subaortic position, either in congenitally corrected transposition 
of the great arteries (cTGA) or transposition of the great arteries 
(TGA) with a previous atrial switch. As a result systemic RV dysfunc-
tion is common in these adult patients with the prevalence 
increasing with age.(13-16) Whilst the number of patients with a pre-
vious atrial switch is decreasing due to the introduction of the 
arterial switch operation in the 1980s,(12) the current population is 
ageing and will therefore be at a higher risk of developing long term 
sequelae of their condition, including ventricular dysfunction, atrial 
arrhythmias and death. 
The systemic RV is known to have extensive myocardial fibrosis and 
hypertrophy and these correlate well with the degree of ventri-
cular dysfunction.(17-19) Angiotensin converting enzyme inhibitors 
(ACEIs) and angiotensin receptor blockers (ARBs) have previously 
been shown to decrease myocardial fibrosis and attenuate ven-
tricular remodelling with a resultant increase in myocardial function 
and decrease in mortality in patients with both asymptomatic and 
symptomatic left ventricular dysfunction.(20-23) There have been 
several small trials using ACEIs and ARBs in patients with a sys-
temic RV but results have been disappointing.(17,24,25) A recent 
placebo-controlled study from the Netherlands studied the effect 
of the ARB valsartan on patients with either a previous atrial repair 
for TGA or cTGA.(26) Eighty eight patients were enrolled, 44 
receiving valsartan and 44 placebo with a follow up of three years. 
The authors found no difference in MRI-derived RVEF, quality of 
life or exercise capacity between the valsartan and placebo group. 
Similarly, beta blockers are known to improve LV function, reverse 
remodelling and reduce morbidity and mortality in patients with 
chronic LV dysfunction.(27,28) Josephson, et al. studied the effect of 
beta blockers in patients with a previous Mustard repair of TGA 
and found a trend towards improved functional status and reduction 
in tricuspid regurgitation.(29) Giardini, et al. also reported a trend 
towards a reduction in RV volumes and increase in ejection fraction 
in patients with a systemic RV receiving carvedilol.(30) However, 
both of these studies were small single centre trials involving very 
small patient numbers. A larger study by Doughan, et al. retro-
spectively examined all patients in their centre with a systemic RV 
receiving carvedilol or metoprolol.(31) They included 31 patients 
but were unable to demonstrate an effect on either RV ejection 
fraction or RV volumes, although they do report an improve-
ment in functional class. Thus, at present evidence remains lacking 
for the use of beta blockers in systemic RV dysfunction from the 
current data available. They are however commonly used for the 
treatment or prevention of atrial arrhythmias in this patient group. 
A recent preliminary study looked at the effect of eplerenone, a 
selective aldosterone antagonist, on patients with a systemic RV.(32) 
They showed that whilst it was associated with reduced levels of 
collagen turnover biomarkers, suggesting a reduction in myo-
cardial fibrosis, there were no changes in MRI derived parameters 
of ventricular function. 
Clinical heart failure in patients with a previous Fontan operation 
is increasingly common with age occurring in up to 40% of patients 
16 years after repair.(14) It is characterised by increasing central 
venous pressures and decreasing cardiac output.(33) Again, pro-
gressive myocardial fibrosis has been identified and is associated 
with ventricular dysfunction(34) and thus neurohormonal modula-
tion, such as with beta blockers, has been suggested as a logical 
approach.(33) Ishibashi, et al. retrospectively evaluated 51 paediatric 
and young adult patients with evidence of heart failure and 
ventricular dysfunction.(35) All patients received carvedilol and were 
followed up for a mean of 11 months. They demonstrated a reduc-
tion in cardiothoracic ratio and an increase in ejection fraction 
following carvedilol therapy, along with a reduction in required 
diuretic dose and an increase in functional class in the >15year old 
group. Two studies have examined the use of ACEIs in a 
univentricular circulation. Hsu, et al. gave infants in the first year of 
life enalapril to improve haemodynamic status and ventricular 
function but showed no benefit.(36) Koulati, et al. similarly found 
no benefit on ventricular function or exercise capacity after 
giving(37) children and young adults with a Fontan circulation 
enalapril for 10 weeks.(38) 
Elevated pulmonary vascular resistance (PVR) is also associated 
with failure of the Fontan circulation(37) with possible causes 
including lack of pulsatile flow in the pulmonary vasculature, micro-
emboli and chronic overexpression of vasoconstrictors such as 
endothelin-1.(39) A reduction in PVR would increase pulmonary 
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blood flow and cardiac filling and thus stroke volume in the presence 
of normal contractility.(40) There is therefore interest in the role of 
selective pulmonary vasodilators in patients with a failing Fontan 
circulation. Ovraet, et al. found no change in exercise capacity after 
three months of bosentan, an endothelin receptor antagonist, in 
children and young adults.(41) However, our group demonstrated 
that bosentan produced a small increase in longitudinal ventri-
cular function and an improvement in NYHA functional class after 
six months of therapy.(42) However, numbers were small in both 
of these studies highlighting the need for larger randomised con-
trolled trials to study the effect on this population. Trials with the 
phoshpodiesterase-5 inhibitor, sildenafil, have so far been more 
promising. Goldberg, et al. looked at the effect on exercise per-
formance of six weeks of sildenafil on 28 children and young adults 
with a Fontan circulation.(40) Whilst they failed to show an increase 
in peak oxygen consumption, they did find a significant improve-
ment in ventilator efficiency during peak and submaximal exercise. 
A further study gave sildenafil to a similar population and after just 
one week demonstrated and increase in ventricular systolic 
elastance and improved ventriculo-arterial coupling.(43) 
IMPLANTABLE CARDIAC DEFIBRILLATORS (ICDs)
Arrhythmias are common in adult congenital heart disease (ACHD) 
patients and are an important determinant in the morbidity and 
mortality of this population(3,8-10,44) with the risk of late sudden 
cardiac death (SCD) being 25-100 times greater than that of an 
aged matched control population,(45) the risk increasing after the 
second decade following surgery. Arrhythmias may be intrinsic to 
the underlying abnormality, such as an accessory pathway in 
Ebstein’s anomaly, or due to long term sequelae from its palli-
ation, such as extensive suture lines, chronic haemodynamic 
disturbances or long term cyanosis.(46,47) The risk of arrhythmias and 
SCD appears to be highest in those with surgically repaired 
Tetralogy of Fallots (TOF),(48) and TGA with an atrial switch.(45,49,50)
Czosek, et al. studied 589 Holter monitors in 189 patients with 
CHD.(51) They found that non-sustained ventricular tachycardia 
(NSVT) was associated with SCD in patients with TOF but not in 
those with previous atrial switches or Fontan operation. They 
concluded that Holter monitors overall have a low positive pre-
dictive value for clinically significant arrhythmias but a high negative 
predictive value. Other high risk features of SCD identified in 
patients with TOF include a QRS duration >180ms on a resting 
ECG,(52) a lengthening QRS late after surgery(53) and inducible 
sustained ventricular tachycardia (VT) during programmed ven-
tricular stimulation.(54)
Kammeraad, et al. also found that the presence of NSVT on Holter 
ECG monitoring was not predictive of SCD in patients with TGA / 
atrial switch.(49) They did however demonstrate an increase risk 
in the presence of symptoms and a previously documented 
atrial arrhythmia. Scwerzman, et al. comment that sustained VT and 
SCD is more common in those patients with a previous Mustard 
operation than previously described and is associated with 
increasing age, severe systemic ventricular dysfunction and a QRS 
duration >140ms.(50) 
Whilst clear guidelines and indications exist for patients with 
ischaemic or dilated cardiomyopathy, there is a lack of universal 
criteria regarding risk stratification and indications for implanta-
tion of ICDs in ACHD patients. Even patients with repaired TOF 
have an incidence of SCD of only 2% per decade(46) thus large 
randomised, prospective studies looking at outcomes of ICDs 
on mortality are difficult. 
Even in the presence of high risk features, concern remains regard-
ing the implantation of ICDs in these patients with several studies 
reporting high rates of complications, including inappropriate 
shocks in 21-47% of patients, mostly due to atrial tachyarrhythmias, 
T-wave over sensing or lead failure.(55-59) 
Khanna, et al. reviewed all transvenous ICD implantations per-
formed in ACHD patients at the Mayo clinic, United States, 
between 1991 and 2008.(60) They report 85 devices in 73 patients 
with the commonest underlying diagnosis being TOF in 44% cases. 
They report a low rate of implant related and long term com-
plications with appropriate shocks occurring in 19% of all patients. 
Appropriate shocks were associated with elevated pressures in the 
subpulmonic ventricle. They also found that inappropriate shocks 
occurred in only 15% of patients which is lower than that reported 
in previous studies. A multi-centre European study by Koyak, et al. 
looked at 136 patients with ACHD who received an ICD.(61) Again, 
the commonest diagnosis was TOF. They, however, found a much 
higher rate of implantation related complications as well as inap-
propriate shocks occurring in 30% patients. Higher appropriate 
shock rates were also described with 29% of patients overall 
receiving at least one appropriate shock. Thus, despite a high 
reported complication rate, they conclude that ICDs are useful in 
the prevention of SCD in this population.
ADVANCED ACHD
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Specific problems can arise in pacing patients with ACHD including 
no venous access to the heart, altered haemodynamics from long 
standing valvular disease making lead placement difficult, extensive 
scar tissue from previous surgery and small vessel size.(59) Further-
more, residual intra-cardiac shunts lead to a risk of thrombus and 
subsequent systemic embolisation. Thus, in some patients, epicardial 
pacing may need to be considered. More recently the develop-
ment of a subcutaneous ICD has added a further option for these 
patients.(62,63) They consist of a pulse generator and subcutaneous 
electrode and negates the need for transvenous access. However, 
they have no integrated pacing function thus are not suitable if 
there is a risk of bradyarrhythmia. They may also increase the 
number of appropriate shocks delivered due to the absence of 
anti-tachycardia pacing. 
Finally, these patients are often young and active. The psychological 
burden of ICD implantation may be greater than in older patients 
with acquired disease, with increased levels of depression and 
anxiety.(59,64,65) These may be further increased in the occurrence 
of inappropriate shocks. Furthermore, they are committed to 
numerous generator changes and possible lead replacements 
throughout their life. It is thus vital that they receive appropriate 
counselling prior to implantation 
CARDIAC RESYNCHRONISATION THERAPY (CRT)
The use of cardiac resynchronisation therapy in heart failure 
secondary to ischaemic and dilated cardiomyopathies is now well 
established with clear indications and guidelines.(66,67) Its role in con-
genital heart disease, however, is less well defined and it may not 
be appropriate to extrapolate the findings of the large trials per-
formed in acquired heart failure to this population.(68,69) ACHD 
patients are a heterogeneous population and frequently have dif-
ferent forms of dyssynchrony, including a predominance of RBBB.(47) 
They are also more likely to have subpulmonic ventricular dys-
function or have a systemic right ventricle or even a univentricular 
circulation. Further complicating factors include patient selection, 
transvenous lead access and access to the chamber or coronary 
sinus.(47,69) As a result the evidence is limited to small studies or 
case studies.
Janousek, et al. in 2009 reported on 109 paediatric or young 
patients with CHD, median age 16.9 years, in a multicentre 
European study.(70) This cohort included 36 patients with a sys-
temic RV and four with a single ventricular circulation. The majority 
of patients had interventricular dyssynchrony secondary to single 
site pacing and only 41% had a transvenous approach. Their results 
show a decrease in systemic ventricular dimensions, an increase in 
systemic ventricular ejection fraction and an improvement in 
\NYHA score. They found that the strongest predictor of an 
improvement in ventricular function is the presence of a systemic 
left ventricle. They further hypothesise that systemic RVs show less 
improvement due to the higher associated degree of systemic AV 
valve regurgitation seen. Similar results were shown by Dubin, et al. 
who demonstrated a benefit in patients with both systemic left and 
right ventricles.(71) In their study, however, no benefit was demon-
strated in univentricular circulations. They comment though that 
only 54% of their patients met the ejection fraction and QRS 
criteria used in adult acquired disease studies, thus concluding that 
the indications in the ACHD population differ from those in 
ischaemic and dilated cardiomyopathy and remain unclear. 
The indication for CRT in failing systemic RVs remains uncertain 
and is also associated with specific difficulties regarding trans-
venous access and lead placement. Systemic ventricular dysfunc-
tion is increasingly common over time in patients with a previous 
Mustard or Senning repair.(14,15) Similarly, most patients with 
congenitally corrected TGA will develop some degree of RV dys-
function, usually occurring by the third decade of life.(16) Janaousek, 
et al. in 2004 studied 8 patients with a systemic RV who under-
went CRT therapy.(72) They demonstrated a decrease in QRS 
duration and interventricular delay and increased RV filling time 
and ejection fraction. However, as in the other studies discussed 
above, the majority of patients had single site pacing induced 
ventricular dyssynchrony as the indication for CRT, making the 
interpretation of the results for unpaced patients unclear. Similar to 
their later paper, discussed above, Janousek, et al. noted no change 
in the severity of right AV valve regurgitation with CRT therapy. 
Thus, for systemic right ventricles, it may be that CRT implanta-
tion should be considered as an adjunct to right AV valve 
intervention.(69,70) 
CARDIAC TRANSPLANTATION IN ACHD
As increasing numbers of patients born with complex congenital 
heart disease reach adulthood, there will be an inevitable rise in 
the number of patients who develop advanced disease in whom 
conventional medical and surgical therapy has failed, with an 
estimated 10-20% of all patients with complex ACHD eventually 
demonstrating the need for a transplant.(73) In many of these 
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patients, heart or heart and lung transplantation is the only defini-
tive treatment to improve survival and quality of life.(74) Trans-
plantation in patients with ACHD, however, has previously been 
perceived to be associated with poor outcome, when compared 
to other indications(75,76) with Taylor, et al. stating “the diagnosis 
of ACHD is a powerful risk factor for death at one year after 
transplant”.(77) Problems specific to this population include com-
plex anatomy often with multiple previous operations(74,76,78) and 
an elevated pulmonary vascular resistance (PVR), a known risk 
factor for early donor organ failure.(79) Further to these, HLA 
sensitisation is common, especially in those patients who have 
undergone previous surgery with a homograft.(80) HLA sensitisa-
tion, as indicated by elevated panel reactive antibodies (PRA), is 
associated with a worse outcome following transplant, especially 
for those with a PRA >25%, as well as decreased chances of 
getting a successful organ match.(81) 
Despite these problems, the numbers of patients with CHD 
being referred for transplantation has increased over the past 
15 years.(74,78) However, the overall proportion of transplants for 
underlying CHD remains small and account for just 2% of all 
transplants performed.(82) Thus, many studies are small, single 
centre studies. 
Irving, et al. looked at all adults with CHD who underwent 
transplantation in a single UK centre.(76) They report on 37 patients, 
41% of whom had a univentricular circulation and 22% had TGA 
with a previous Mustard or Senning repair. They found a 30 day 
survival of 70.3% which was higher than patients with other 
indications; however their long term survival was comparable. Two 
larger studies from the US examined all transplants recorded in a 
nationwide registry and database.(74,78) However, unlike Irving, et al., 
the type of CHD was not recorded. Davies, et al. identified 1 035 
adult patients with CHD who were listed for primary cardiac 
transplantation (2.5% of the total number).(78) They found that 
patients with CHD were on the waiting list for a longer time and, 
again demonstrated a higher early mortality in those with CHD 
(18.9% vs 9.6%) but an equivalent 10 year mortality (52.8% vs 
53.6%). Similar results were also found by Patel, et al. who further 
reported that patients with CHD who underwent transplanta-
tion had significantly longer intraoperative ischaemic times.(74) 
Furthermore they noted that the underlying causes for the excess 
early mortality included complex anatomy, right ventricular failure 
due to elevated PVR and a more debilitated condition prior to 
surgery.
Patients with a univentricular circulation account for the greatest 
number of CHD referrals for cardiac transplantation from the 
age of six months to adulthood.(83) However, patients with two 
ventricle hearts have been shown to have better outcome than 
those with single ventricle hearts.(84) Furthermore, Griffiths, et al. 
demonstrated a worse outcome in patients with a Fontan circula-
tion who underwent cardiac transplantation for failed Fontan 
physiology rather than primary ventricular dysfunction (96.1% vs 
89% one year survival).(85) They go on to suggest that these 
patients should be considered for transplantation at an earlier 
stage of their disease or considered for alternative medical or 
surgical interventions.
It is clear that patients with CHD are a heterogeneous popula-
tion and it is difficult to apply results from studies of patients 
undergoing transplantation for acquired cardiac disease. The criteria 
for referring these patients may not yet be properly defined 
resulting in some patients being listed too late.(78) Furthermore, due 
to the complex issues associated with these patients and the 
relatively small numbers involved, these patients should be managed 
in large centres with the necessary experience and expertise to 
optimise their outcome.(76) 
VENTRICULAR ASSIST DEVICES
The use of ventricular assist devices (VADs) is becoming increas-
ingly widespread in patients with acquired heart failure(86) as either 
a bridge to transplant or recovery.(79,87-89) Whilst their use in 
ACHD is increasing, their success is mainly reported in a number of 
case reports with no large randomised trial available to date. 
Furthermore, patients with CHD listed for cardiac transplanta-
tion are less likely to have mechanical support, including a VAD, 
than those with acquired heart failure.(78,90) 
As discussed above, univentricular hearts account for the greatest 
number of CHD referrals for transplant. Thus, there has been 
much interest in the benefit of VADs in this growing population. 
A number of case reports have shown that VADs in patients 
with a Fontan circulation can facilitate the recovery of circula-
tory, metabolic and pulmonary abnormalities.(91,92) They can be 
beneficial if the underlying problem is ventricular dysfunction(93) 
or normal ventricular function but high venous pressures.(94) 
However, previous studies have shown that showed that in chil-
dren with univentricular circulations, the use of the Berlin heart 
VAD was associated with only a 50% chance of survival to 
transplantation compared to an overall survival of 70-86% in all 
children with a VAD.(95-97) New devices that specifically increase 
ADVANCED ACHD
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the blood flow through the systemic venous return through the 
lungs are being designed, for example a pump in the IVC and 
hepatic blood flow to give mechanical cavopulmonary assistance.(98) 
Similarly, case reports have reported some success with the use of 
VADs in patients with systemic right ventricles.(99,100) Joyce, et al. 
however report complications arising from the positioning of 
the cannulae due anatomical differences in the right ventricle.(99) 
END OF LIFE CARE
The role of early and proactive discussion regarding end of 
life (EOL) care is of proven benefit in oncology and acquired 
heart failure(101-103) and leads to less aggressive medical care at the 
end of life and earlier referral for hospice care. However, a recent 
study by Tobler, et al. reported that in a survey of adults with 
CHD, only 1% of patients had discussed EOL planning, whereas 
50% of their physicians reported regularly discussing these 
issues.(104) Furthermore they found that 78% of these patients 
wished to discuss EOL issues, 62% wishing for this to be done at 
an early stage and this was irrespective of disease severity. A 
further study by this group looked at the experience of adults 
with CHD who died in hospital and found that only 10% had docu-
mented EOL discussions with active resuscitation less likely to 
happen in these patients.(105) 
As cardiologists we frequently extrapolate our experience from 
that gained in acquired heart failure including in EOL care. How-
ever, patients with CHD have important differences. Firstly they 
have a lifelong illness and there is often no triggering event for 
the deterioration, making timing of discussion difficult to judge in 
many cases.(106) Furthermore, these patients are young with the 
median age of patients with severe CHD being just 29 years.(4) 
With increasing survivors of the Norwood operation now reaching 
adulthood, the number of young adults is likely to increase.
Oncologists have identified that young patients have unique needs, 
often needing a more collaborative approach with their physician 
with regards to their care planning.(107) A previous study in young 
patients with cancer showed that EOL discussions often don’t 
occur until very close to death, with barriers to communication 
including a desire to protect and difficulties dealing with personal 
emotions.(108)
There is frequently a difficult balance between life-prolonging 
interventions, such as transplantation, and end of life care. Ideally 
patients should have a parallel approach to their care with a study 
looking at patients with acquired heart failure being assessed for 
VADs showing that this approach leads to clearer post-operative 
care and more effective management of complications.(109) 
As the number of patients with advanced disease continues to 
increase, we must acknowledge that this is an important, and 
currently often lacking, part of our patients’ on-going care. EOL 
discussion and planning should become a routine part of their 
assessment and their unique needs and preferences addressed.(106) 
CONCLUSION
Patients with complex congenital heart disease are a growing 
population and remain at lifelong risk of complications. Whilst 
drug therapy is usually the first line treatment in advanced disease, 
results from conventional therapy are disappointing, although 
there are promising results from the use of selective pulmonary 
vasodilators in patients with a Fontan circulation. However, whilst 
medical options may slow down the progression and even delay 
the need for surgical intervention or transplantation, they do not 
halt the inevitable decline altogether. Whilst transplantation in 
patients with CHD is associated with higher early mortality post 
transplantation, the long term survival is equivalent to that in 
acquired heart failure. Many patients though are not suitable for 
listing or die on the waiting list. These issues highlight the impor-
tance of end of life discussion and planning, an area that, as a 
speciality, we frequently fail to address. Delivering optimal EOL 
care in this population remains one of the big challenges we 
continue to face. Finally, CHD is a lifelong condition and thus 
requires lifelong access to health care. Many of the treatment 
options discussed in this review, especially devices and cardiac 
transplantation may be prohibitively expensive to some patients 
where free health care is not available to all. 
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